Effects of arsenite and UVA-1 radiation on calcineurin signaling

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 735, Issue 1-2, 2012, Pages 32-38

  Musson, Ruben E A ^a   Mullenders, Leon H F ^a   Smit, Nico P M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arsenite; Calcineurin; NFAT; Reactive oxygen species; Skin carcinogenesis; UVA radiation

Indexed keywords

ARSENIC TRIOXIDE; CALCINEURIN; CYCLOSPORIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA REPAIR; GRAFT RECIPIENT; GRAFT REJECTION; LEUKEMIA CELL LINE; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CELL; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION;

ARSENITES; CALCINEURIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; JURKAT CELLS; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; SKIN; SUPEROXIDES; TRANSCRIPTION FACTOR RELA; ULTRAVIOLET RAYS;

EID: 84863006007     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2012.04.007     Document Type: Article

References (74)

1. Klaunig J.E., Kamendulis L.M., Hocevar B.A. Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 2010, 38:96-109.
2. Rusnak F., Mertz P. Calcineurin: form and function. Physiol. Rev. 2000, 80:1483-1521.
3. Aramburu J., Heitman J., Crabtree G.R. Calcineurin: a central controller of signalling in eukaryotes. EMBO Rep. 2004, 5:343-348.
4. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 1997, 15:707-747.
5. Horsley V., Pavlath G.K. NFAT: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 2002, 156:771-774.
6. Namgaladze D., Hofer H.W., Ullrich V. Redox control of calcineurin by targeting the binuclear Fe(2+)-Zn(2+) center at the enzyme active site. J. Biol. Chem. 2002, 277:5962-5969.
7. Musson R.E., Smit N.P. Regulatory mechanisms of calcineurin phosphatase activity. Curr. Med. Chem. 2011, 18:301-315.
8. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
9. Maluccio M., Sharma V., Lagman M., Vyas S., Yang H., Li B., Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003, 76:597-602.
10. Musson R.E., Hensbergen P.J., Westphal A.H., Temmink W.P., Deelder A.M., van Pelt J., Mullenders L.H., Smit N.P. UVA1 radiation inhibits calcineurin through oxidative damage mediated by photosensitization. Free Radic. Biol. Med. 2011, 50:1392-1399.
11. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999, 284:339.
12. Mammucari C., Tommasi di Vignano A., Sharov A.A., Neilson J., Havrda M.C., Roop D.R., Botchkarev V.A., Crabtree G.R., Dotto G.P. Integration of notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev. Cell 2005, 8:665-676.
13. Ryeom S., Baek K.H., Rioth M.J., Lynch R.C., Zaslavsky A., Birsner A., Yoon S.S., McKeon F. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 2008, 13:420-431.
14. Krieg C., Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin. Cancer Biol. 2009, 19:76-83.
15. Wu X., Nguyen B.C., Dziunycz P., Chang S., Brooks Y., Lefort K., Hofbauer G.F., Dotto G.P. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010, 465:368-372.
16. Dotto G.P. Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis. Cancer Res. 2011, 71:2029-2033.
17. Thoms K.M., Kuschal C., Oetjen E., Mori T., Kobayashi N., Laspe P., Boeckmann L., Schön M.P., Emmert S. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp. Dermatol. 2011, 20:232-236.
18. Shannon R.L., Strayer D.S. Arsenic-induced skin toxicity. Hum. Toxicol. 1989, 8:99-104.
19. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 2003, 533:37-65.
20. Yu H.S., Liao W.T., Chai C.Y. Arsenic carcinogenesis in the skin. J. Biomed. Sci. 2006, 13:657-666.
21. Rossman T.G., Uddin A.N., Burns F.J. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol. Appl. Pharmacol. 2004, 198:394-404.
22. Cooper K.L., Liu K.J., Hudson L.G. Enhanced ROS production and redox signaling with combined arsenite and UVA exposure: contribution of NADPH oxidase. Free Radic. Biol. Med. 2009, 47:381-388.
23. Sun Y., Kojima C., Chignell C., Mason R., Waalkes M.P. Arsenic transformation predisposes human skin keratinocytes to UV-induced DNA damage yet enhances their survival apparently by diminishing oxidant response. Toxicol. Appl. Pharmacol. 2011, 255:242-250.
24. Hughes M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 2002, 133:1-16.
25. Hamadeh H.K., Trouba K.J., Amin R.P., Afshari C.A., Germolec D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 2002, 69:306-316.
26. Ren X., McHale C.M., Skibola C.F., Smith A.H., Smith M.T., Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ. Health Perspect. 2011, 119:11-19.
27. Hartwig A., Groblinghoff U.D., Beyersmann D., Natarajan A.T., Filon R., Mullenders L.H. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis 1997, 18:399-405.
28. Nollen M., Ebert F., Moser J., Mullenders L.H., Hartwig A., Schwerdtle T. Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression. Mol. Nutr. Food Res. 2009, 53:572-582.
29. Shi H., Shi X., Liu K.J. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol. Cell. Biochem. 2004, 255:67-78.
30. Ding W., Hudson L.G., Liu K.J. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol. Cell. Biochem. 2005, 279:105-112.
31. Flora S.J. Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med. 2011, 51:257-281.
32. Chou W.C., Jie C., Kenedy A.A., Jones R.J., Trush M.A., Dang C.V. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4578-4583.
33. Vahidnia A., Romijn F., van der Voet G.B., de Wolff F.A. Arsenic-induced neurotoxicity in relation to toxicokinetics: effects on sciatic nerve proteins. Chem. Biol. Interact. 2008, 176:188-195.
34. Vahidnia A., van der Straaten R.J., Romijn F., van Pelt J., van der Voet G.B., de Wolff F.A. Mechanism of arsenic-induced neurotoxicity may be explained through cleavage of p35 to p25 by calpain. Toxicol. In Vitro 2008, 22:682-687.
35. Gharibzadeh S., Hoseini S.S. Arsenic exposure may be a risk factor for Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 2008, 20:501.
36. Gong G., O'bryant S.E. The arsenic exposure hypothesis for Alzheimer disease. Alzheimer Dis. Assoc. Disord. October-December 2010, 24:311-316.
37. Gong C.X., Singh T.J., Grundke-Iqbal I., Iqbal K. Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2B (calcineurin). J. Neurochem. 1994, 62:803-806.
38. Gong C.X., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 1994, 61:765-772.
39. Ladner C.J., Czech J., Maurice J., Lorens S.A., Lee J.M. Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J. Neuropathol. Exp. Neurol. 1996, 55:924-931.
40. Kayyali U.S., Zhang W., Yee A.G., Seidman J.G., Potter H. Cytoskeletal changes in the brains of mice lacking calcineurin A alpha. J. Neurochem. 1997, 68:1668-1678.
41. Lian Q., Ladner C.J., Magnuson D., Lee J.M. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp. Neurol. 2001, 167:158-165.
42. Supnet C., Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010, 47:183-189.
43. Hu Y., Su L., Snow E.T. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat. Res. 1998, 408:203-218.
44. Bogumil R., Namgaladze D., Schaarschmidt D., Schmachtel T., Hellstern S., Mutzel R., Ullrich V. Inactivation of calcineurin by hydrogen peroxide and phenylarsine oxide. Evidence for a dithiol-disulfide equilibrium and implications for redox regulation. Eur. J. Biochem. 2000, 267:1407-1415.
45. Ding J., Li J., Xue C., Wu K., Ouyang W., Zhang D., Yan Y., Huang C. Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J. Biol. Chem. 2006, 281:24405-24413.
46. Conde P., Acosta-Saavedra L.C., Goytia-Acevedo R.C., Calderon-Aranda E.S. Sodium arsenite-induced inhibition of cell proliferation is related to inhibition of IL-2 mRNA expression in mouse activated T cells. Arch. Toxicol. 2007, 81:251-259.
47. Smit N.P., Van Rossum H.H., Romijn F.P., Sellar K.J., Breetveld M., Gibbs S., Van Pelt J. Calcineurin activity and inhibition in skin and (epi)dermal cell cultures. J. Invest. Dermatol. 2008, 128:1686-1690.
48. Manger B., Hardy K.J., Weiss A., Stobo J.D. Differential effect of cyclosporin A on activation signaling in human T cell lines. J. Clin. Invest. 1986, 77:1501-1506.
49. Sellar K.J., van Rossum H.H., Romijn F.P., Smit N.P., de Fijter J.W., van Pelt J. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. Anal. Biochem. 2006, 358:104-110.
50. Dekter H.E., Romijn F.P., Temmink W.P., van Pelt J., de Fijter J.W., Smit N.P. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal. Biochem. 2010, 403:79-87.
51. Smit N., Musson R., Romijn F., van Rossum H., van Pelt J. Effects of ultraviolet A-1 radiation on calcineurin activity and cytokine production in (skin) cell cultures. Photochem. Photobiol. 2010, 86:360-366.
52. Viola J.P., Carvalho L.D., Fonseca B.P., Teixeira L.K. NFAT transcription factors: from cell cycle to tumor development. Braz. J. Med. Biol. Res. 2005, 38:335-344.
53. Robbs B.K., Cruz A.L., Werneck M.B., Mognol G.P., Viola J.P. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol. Cell. Biol. 2008, 28:7168-7181.
54. Mancini M., Toker A. NFAT proteins: emerging roles in cancer progression. Nat. Rev. Cancer 2009, 9:810-820.
55. Giese T., Sommerer C., Zeier M., Meuer S. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin. Immunol. 2009, 132:305-311.
56. Shibasaki F., Kondo E., Akagi T., McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997, 386:728-731.
57. Santini M.P., Talora C., Seki T., Bolgan L., Dotto G.P. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9575-9580.
58. Al-Daraji W.I., Malak T.T., Prescott R.J., Abdellaoui A., Ali M.M., Dabash T., Zelger B.G., Zelger B. Expression, localisation and functional activation of NFAT-2 in normal human skin, psoriasis, and cultured keratocytes. Int. J. Clin. Exp. Med. 2009, 2:176-192.
59. Sommerer C., Giese T., Schmidt J., Meuer S., Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008, 85:15-21.
60. Paul D.S., Hernández-Zavala A., Walton F.S., Adair B.M., Dedina J., Matousek T., Stýblo M. Examination of the effects of arsenic on glucose homeostasis in cell culture and animal studies: development of a mouse model for arsenic-induced diabetes. Toxicol. Appl. Pharmacol. 2007, 222:305-314.
61. Wei Q., Holzer M., Brueckner M.K., Liu Y., Arendt T. Dephosphorylation of tau protein by calcineurin triturated into neural living cells. Cell. Mol. Neurobiol. 2002, 22:13-24.
62. Giasson B.I., Sampathu D.M., Wilson C.A., Vogelsberg-Ragaglia V., Mushynski W.E., Lee V.M. The environmental toxin arsenite induces tau hyperphosphorylation. Biochemistry 2002, 41:15376-15387.
63. Sommer D., Fakata K.L., Swanson S.A., Stemmer P.M. Modulation of the phosphatase activity of calcineurin by oxidants and antioxidants in vitro. Eur. J. Biochem. 2000, 267:2312-2322.
64. Lynn S., Gurr J.R., Lai H.T., Jan K.Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 2000, 86:514-519.
65. King M.M. Modification of the calmodulin-stimulated phosphatase, calcineurin, by sulfhydryl reagents. J. Biol. Chem. 1986, 261:4081-4084.
66. Wenczl E., Van der Schans G.P., Roza L., Kolb R.M., Timmerman A.J., Smit N.P., Pavel S., Schothorst A.A. (Pheo)melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes. J. Invest. Dermatol. 1998, 111:678-682.
67. Smit N.P., van Nieuwpoort F.A., Marrot L., Out C., Poorthuis B., van Pelt H., Meunier J.R., Pavel S. Increased melanogenesis is a risk factor for oxidative DNA damage - study on cultured melanocytes and atypical nevus cells. Photochem. Photobiol. 2008, 84:550-555.
68. Li N., Karin M. Is NF-kappaB the sensor of oxidative stress?. FASEB J. 1999, 13:1137-1143.
69. Schoonbroodt S., Piette J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem. Pharmacol. 2000, 60:1075-1083.
70. Reelfs O., Tyrrell R.M., Pourzand C. Ultraviolet a radiation-induced immediate iron release is a key modulator of the activation of NF-kappaB in human skin fibroblasts. J. Invest. Dermatol. 2004, 122:1440-1447.
71. Djavaheri-Mergny M., Gras M.P., Mergny J.L., Dubertret L. UV-A-induced decrease in nuclear factor-kappaB activity in human keratinocytes. Biochem. J. 1999, 338(Pt 3):607-613.
72. 2+/calcineurin signalling in cells of the immune system. Biochem. Biophys. Res. Commun. 2003, 311:1117-1132.
73. Ravi R., Bedi A. NF-kappaB in cancer - a friend turned foe. Drug Resist. Updat. 2004, 7:53-67.
74. Ullrich V., Namgaladze D., Frein D. Superoxide as inhibitor of calcineurin and mediator of redox regulation. Toxicol. Lett. 2003, 139:107-110.